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Abstract
Background: One consistent finding in autism spectrum disorders (ASD) is a decreased level of the pineal gland
hormone melatonin and it has recently been demonstrated that this decrease to a large extent is due to low
activity of the acetylserotonin O-methyltransferase (ASMT), the last enzyme in the melatonin synthesis pathway.
Moreover, mutations in the ASMT gene have been identified, including a splice site mutation, that were associated
with low ASMT activity and melatonin secretion, suggesting that the low ASMT activity observed in autism is, at
least partly, due to variation within the ASMT gene.
Methods: In the present study, we have investigated all the genes involved in the melatonin pathway by mutation
screening of AA-NAT (arylalkylamine N-acetyltransferase), ASMT, MTNR1A, MTNR1B (melatonin receptor 1A and 1B)
and GPR50 (G protein-coupled receptor 50), encoding both synthesis enzymes and the three main receptors of
melatonin, in 109 patients with autism spectrum disorders (ASD). A cohort of 188 subjects from the general
population was used as a comparison group and was genotyped for the variants identified in the patient sample.
Results: Several rare variants were identified in patients with ASD, including the previously reported splice site
mutation in ASMT (IVS5+2T>C). Of the variants affecting protein sequence, only the V124I in the MTNR1B gene was
absent in our comparison group. However, mutations were found in upstream regulatory regions in three of the
genes investigated, ASMT, MTNR1A, and MTNR1B.
Conclusions: Our report of another ASD patient carrying the splice site mutation IVS5+2T>C, in ASMT further
supports an involvement of this gene in autism. Moreover, our results also suggest that other melatonin related
genes might be interesting candidates for further investigation in the search for genes involved in autism
spectrum disorders and related neurobehavioral phenotypes. However, further studies of the novel variants
identified in this study are warranted to shed light on their potential role in the pathophysiology of these
disorders.
Background
Autism spectrum disorders (ASDs) are pervasive devel-
opmental disorders that include Autistic disorder,
Asperger syndrome, and pervasive developmental disor-
der-not otherwise specified (PDD-NOS). These condi-
tions are complex, behaviorally-defined syndromes with
variable severity and highly diverse symptomatology and
etiologies, characterized by impairments in social inter-
action and communication and patients often display
repetitive behaviors, abnormal movements, and sensory
dysfunction [1]. Moreover, the severity of mental
retardation (MR) is highly variable among cases with
ASD [2].
Twin studies have demonstrated a much higher con-
cordance for ASD in monozygotic (>70%) than in dizy-
gotic twins (0-10%), suggesting genetic factors to play a
major role in the etiology [3,4]. However, although the
high heritability of autism is well established and inher-
ited forms of the disorder have been demonstrated,
most autism cases seem to occur as sporadic cases [5].
Moreover, several monogenic disorders, such as fragile
X syndrome, Rett syndrome and tuberous sclerosis, are
well known causes of autism like behavior patterns, and
recently, rare mutations and copy number variations
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have been found to be causative or contributory factors
for autism spectrum disorders [6-9]. These observations,
together with the early age of onset, indicate that rare,
high impact, genetic variants may play an important role
in the etiology of ASD [5].
Sleep disturbances are often reported in patients with
ASD [10], suggesting that neuroendocrine functions
involved in the circadian sleep-wake cycle may be altered
in these disorders. Moreover, it is well established that
mutations altering the biological clock can cause severe
sleep problems by modifying sleep phase or duration
[11]. Melatonin, a hormone secreted by the pineal gland
in the brain, serves as the body’s signal for darkness and
is involved in various physiologic functions, including
sleep induction, circadian rhythm regulation, and
immune response [12]. Melatonin as a medication has
been shown to improve the sleep of patients with ASD
[13,14], suggesting that the endogenous level of this hor-
mone may not be sufficient to adequately set the clock in
these patients. Indeed, one consistent biological finding
in autism is low levels of melatonin [15-18], and in a
recent study, it could be demonstrated that this decrease
of melatonin seems to be due to low activity of the acet-
ylserotonin O-methyltransferase (ASMT), the last
enzyme in the melatonin synthesis [15].
In the same study, several mutations in the ASMT
gene were identified, including a splice site mutation,
IVS5+2T>C, that were associated with low ASMT activ-
ity and melatonin secretion, suggesting that the low
ASMT activity in autism is, at least partly, due to varia-
tion within the ASMT gene. In a replication study inves-
tigating almost 400 ASD patients from Italy, Finland,
and the UK, several mutations in the ASMT gene were
identified, including the previously reported splice site
mutation and a novel stop-mutation (R319X) [19].
Recently, further support for an involvement of the
ASMT gene in ASD was presented in a Multiplex Liga-
tion-dependent Probe Amplification (MLPA) study
showing that a duplication in the ASMT gene was sig-
nificantly more common in ASD, as compared to con-
trols [20], suggesting that the expression of the ASMT
protein may be altered in ASD patients. In addition,
other genes implicated in circadian rhythm regulation
and central effects of melatonin, i.e., the clock genes,
have also been found to be associated with autism
[21,22]. Taken together, previous data suggest that the
ASMT gene and the melatonin signaling pathway may
play an important role in the etiology of autism spec-
trum disorders.
The aim of the present study was to search for muta-
tions in genes involved in the melatonin pathway in
cases of ASD. To this end, we performed mutation
screening of all the genes of the melatonin pathway, i.e.,
AA-NAT, ASMT, MTNR1A, MTNR1B and GPR50, in
109 subjects with ASD. Hence, the focus of this study
was on identifying rare variants within these genes,
rather than on common polymorphisms.
Methods
Patient recruitment and clinical assessment
In total, 109 patients with ASD from two different
populations were included in this study. In the first
population, 65 patients (39 males and 26 females) were
recruited at a tertiary neuropsychiatric outpatient unit at
Mölndals Hospital, Göteborg, Sweden. Thirty-two of
these patients met the criteria for autistic disorder and
33 patients were considered to have pervasive develop-
mental disorder not otherwise specified (PDD-NOS); 24
and 28 of the patients were also diagnosed with moder-
ate and severe mental retardation, respectively. The sec-
ond patient cohort consisted of 44 ASD patients (30
males and 14 females), recruited from several child and
psychiatric outpatient clinics in Stockholm county as
well as from the neuropediatric department in Astrid
Lindgrens hospital and the neuropediatric department at
Sachsska childrens hospital, Stockholm, Sweden. In the
second cohort, 26 of the patients met the criteria for
autistic disorder, 13 of the patients were considered to
have pervasive developmental disorder not otherwise
specified (PDD-NOS), 5 met the criteria for Asperger’s
syndrome, and 21 of the 44 patients had a mental retar-
dation ranging from mild to moderate. All patients from
both populations were diagnosed based on clinical eva-
luation by experienced clinicians using DSM-IV criteria,
and the Autism Diagnostic Interview-Revised (ADI-R),
and patients diagnosed with medical conditions related
to autism and mental retardation, including major chro-
mosomal abnormalities, fragile X syndrome, and tuber-
ous sclerosis, were excluded from the study. The vast
majority of included patients were of Swedish origin and
the control sample used in this study consisted of 188
(94 male and 94 female) Swedish subjects recruited
from the general population in Gothenburg, Sweden
[23]. The control group in this study served only to
investigate if mutations identified in patients were pre-
sent also in the general population, hence, the control
group was not matched to the patient group with
respect to age and gender.
The study was conducted in accordance with the
declaration of Helsinki and approved by the local
Research Ethics Boards. Written informed consent was
obtained from parents or legal guardians, and, if possible
(i.e. if the patient did not have severe MR) from
patients, as well as from controls.
DNA analysis
Mutation screening was performed by direct sequencing
of the exons, the exon-intron boundaries, the 5’ UTR
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and the proximal promoter of AA-NAT, ASMT,
MTNR1A, MTNR1B, and GPR50. Genotyping of healthy
controls for rare variants identified by mutation screen-
ing was performed using direct sequencing, pyrosequen-
cing technology (Pyrosequencing AB, Uppsala, Sweden)
or RFLP, restriction fragment length polymorphism, (the
MTNR1B c.-39G, C>A, A) using Cfr3I (Sau96I). Primer
sequences and PCR-conditions are summarized in addi-
tional file 1 and 2: supplemental table S1 and S2. The
ClustalW alignment program http://www.ebi.ac.uk/clus-
talw/ was used to study conservation of the mutation
sites among different species. The possible functional
impact of amino acid changes was predicted by the
PolyPhen [24](Polymorphism Phenotyping) program
http://coot.embl.de/PolyPhen/) which makes predictions
based on sequence annotation and alignment as well as
structural information and SIFT [25](Sorting Intolerant
From Tolerant) http://blocks.fhcrc.org/sift/SIFT.html),
which use sequence homology for prediction. Identifica-
tion of putative binding sites for transcription factors
was performed using TFsitescan http://www.ifti.org/cgi-
bin/ifti/Tfsitescan.pl and the TRANSFAC database [26].
Analytical plan
The goal of this study was to search for mutations in
genes involved in the melatonin pathway in cases of
ASD. To this end, we performed mutation screening of
all the genes of the melatonin pathway (AA-NAT,
ASMT, MTNR1A, MTNR1B and GPR50) by direct
sequencing. Identified variants were analyzed using dif-
ferent bioinformatic tools (above), however, we did not
have the possibility to perform functional analyses in
our laboratory. Moreover, to assess if identified variants
were present also in the general population, we geno-
typed a reference group of subjects recruited from the
general population in the same geographical area as the
patients. However, since our main goal was to study
rare variants, rather than common polymorphisms, and
since our samples are too small for meaningful statistical
comparisons, we did not perform any case-control asso-
ciation studies using the genotype data of common poly-
morphisms identified in the mutation screening.
Results
Six rare variants in the investigated genes were found
during the screen (Table 1). The previously reported
splice site mutation, IVS5+2T>C, in ASMT [15,19], was
in our study identified in one patient with autistic disor-
der and severe mental retardation. Of the identified
mutations, only the V124I variant in MTNR1B (Table 1)
gives rise to an amino acid change. Our analyses using
ClustalW revealed that this valine residue at amino acid
position 124 is conserved through all vertebrates, and
also between MTNR1A and MTNR1B (Figure 1). How-
ever, computer based prediction of the functional effect
this mutation, using PolyPhen [24] and SIFT [25],
revealed negative results (Table 1). Moreover, mutations
were found upstream of the transcription start in three
of the genes investigated. In ASMT, the c.-376G>A var-
iant (also found in one control) is located in close vici-
nity to a binding site for CRX (Figure 2A) and the
c.-158C>T variant (not present in controls) in MTNR1A
potentially alter the binding of the transcription factors
CREB1 and AP-2 (Figure 2B). In addition, two variants
that were not present in the control group, c.-38C>T in
ASMT and c.-39G, C>A, A in MTNR1B, are located in
the 5’UTR region, hence, potentially altering the transla-
tion efficiency of the mRNA and thereby the expression
of the protein encoding it (Figure 2A and 2C,
respectively).
The splice site mutation, IVS5+2T>C, and the 5’UTR
variant in ASMT were identified in patients with autistic
disorder and PDD-NOS, respectively. The promoter var-
iant in MTNR1A was identified in a patient with PDD-
NOS and the two MTNR1B mutations were identified
in one patient with PDD-NOS (c.-39GC>AA) and one
patient with autistic disorder (V124I). Interestingly, of
the patients carrying variants that were not present in
the unaffected group, only those with the splice site
mutation in ASMT, and the non-synonymous V124I in
MTNR1B met the diagnostic criteria for autistic disorder
[additional file 3: Supplemental Table S3]. Moreover,
four of the five patients carrying variants not present in
controls have had seizures and/or diagnosed epilepsy
and four of the five patients also displayed moderate to
severe MR. For more detailed clinical information on
the patients carrying the identified mutations, see addi-
tional file 3: Supplemental Table S3.
Common, previously reported, SNPs were identified at
frequencies comparable to those found in the databases
Table 1 Sequence variants identified in ASMT, MTNR1A,










ASMT c.-376G>A - 1 1
ASMT c.-38C>T - 1 0
ASMT IVS5+2T>C - 1 0
MTNR1A c.-158C>T - 1 0
MTNR1B c.370G>A V124I* 1 0
MTNR1B c.-39GC>AA - 1 0
* Predicted not to have any major effect on protein function, as assessed by
Polyphen and SIFT.
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(data not shown). The two non-synonymous SNPs
rs61747139 (K243R) in MTNR1B, and rs62620754
(S493N) in GPR50 were also genotyped in our reference
group and the rare alleles of these polymorphisms were
found to have similar frequencies in our non-patient
cohort. Moreover, none of these variants were predicted
to have any major effect on the encoded protein,
according to computer based prediction.
Discussion
In the present study, several rare variants were found in
melatonin related genes in patients with ASD. Most
importantly, the previously reported [15,19] splice site
mutation, IVS5+2T>C, in ASMT was once again found
in a patient with autistic disorder. To our knowledge,
this mutation has now been found in six patients with
ASD, two parents and only one control. Moreover, this
variant has been shown to have a dramatic effect on
melatonin synthesis, both in cultured cell lines and in
vivo [15]. The other two variants identified in ASMT in
our study were situated in upstream regulatory regions
of the gene, and might therefore affect the expression of
the ASMT-protein. This finding is in line with a recent
study by Cai and coworkers [20], who found that a
duplication in the ASMT gene was significantly more
common in ASD, as compared to controls [20], thus
suggesting that the expression of the ASMT protein
may be altered in ASD patients. Moreover, three differ-
ent transcripts of the ASMT gene have been identified
The identification of mutations in the genes encoding
melatonin receptors suggests that also variants in other
melatonin related genes might be implicated in the
abnormal melatonin metabolism observed in ASD.
Although the functional effects of the novel mutations
were not assessed by laboratory assays in our study,
bioinformatics analyses suggest that some of the variants
identified indeed may influence the encoded protein.
First, one of the novel variants identified, the V124I in
the in the third transmembrane domain of the
MTNR1B protein, is conserved through all vertebrates
and among the three melatonin receptors, including
GPR50 (figure 1). The most interesting of the identified
variants were identified in patients for which we did not
have access to DNA from parents and/or other relatives,
hence, we do not know how these alleles are transmitted
or whether they have appeared de novo in the patients.
Further studies that screen ASD-patients for genetic var-
iants in melatonin-related genes thus are highly
warranted.
In summary, our identification of the functional splice
site mutation in ASMT in yet another patient with autis-
tic disorder support the notion that melatonin may be
involved in the psychopathology of autism. Since mela-
tonin regulates the rhythmic expression of clock genes
in the hypothalamus [27], our results also indirectly sup-
port previous studies implicating clock genes in autism
[22]. Although only one of the six mutations identified
in our screen was present also in controls, our study
sample is too small to conclude that mutations in mela-
tonin related genes are enriched in patients with ASD.
However, it cannot be excluded that some of the muta-
tions found in melatonin related genes may infer an
increased risk for circadian rhythm dysfunction in a sub-
group of ASD patients. Moreover, the presence of sei-
zures and moderate to severe MR in four of the five
patients with the observed variants may suggest a
broader role for melatonin related genes in neurodeve-
lopmental disorders.
Conclusions
Our findings suggest that melatonin related genes in
general and ASMT in particular may be important can-
didates for further investigation in the search for genes
involved in autism spectrum disorders and related neu-
robehavioral phenotypes. However, further studies of
the novel variants identified in this study are warranted
to shed light on their potential role in the pathophysiol-
ogy of these disorders.
Figure 1 Peptide sequence alignment of a portion of the MTNR1B-protein from different species (orthologous to the human residues
106-150), and from the human paralogues MTNR1A and GPR50. Conservation of the Valine 124 residue is indicated in green.
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Figure 2 Sequence and variations located in the promoter sequences of the ASMT (A), MTNR1A (B), andthe MTNR1B (C) genes. Rare
variants identified in ASD patients in our screen are indicated in red. Putative binding sites for major known transcription factors and
transcription factor binding sites close to identified mutations are indicated. CCAC-boxes are indicated in yellow and the CAAT-BOX in ASMT is
indicated in dark green. As reported previously, TATA-boxes are not present in any of the promoter regions examined. The two SNPs (rs4446909
and rs5989681) in ASMT previously associated [15] with autism and low transcript levels are indicated in pink.
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Additional file 1: Supplementary Table S1. PCR primers and
conditions used for sequencing in this study. This table contains all
primer sequences and PCR conditions used in the sequencing of the
genes in this study.
Additional file 2: Supplementary Table S2. PCR primers used for
genotyping in this study. This table contains all primer sequences and
PCR conditions used in the genotyping assays of this study.
Additional file 3: Supplementary Table S3. Clinical features of
patients carrying mutations not observed in controls. This table
contains clinical information of the patients carrying mutations identified
in this study.
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